Semaglutide

← Pipeline

Semaglutide

Novo Nordisk · Alzheimer's disease
Late-stage completed completed CT.gov grounded

A high-visibility metabolic intervention program that tests whether GLP-1 biology can matter in Alzheimer's disease.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
GLP-1 receptor agonism
Modality
small molecule / peptide metabolic therapy
Phase
Late-stage
Status
completed
Recruitment
completed
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Novo Nordisk
Trial IDs
NCT04777396
ClinicalTrials.gov exact matches: NCT04777396

Regions and recruitment

Active in 37 regions
United States Argentina Australia Austria Belgium Brazil Bulgaria Canada Czechia Denmark Finland France Germany Greece Hungary Ireland Israel Italy Japan Mexico Netherlands Norway Poland Portugal Romania Russia Serbia Slovakia Slovenia South Africa South Korea Spain Sweden Switzerland Turkey (Türkiye) Ukraine United Kingdom

Indication tags

Alzheimer's metabolic interventions

Milestones and catalysts

Last milestone
EVOKE put a major metabolic-neurodegeneration bet into a late-stage Alzheimer's setting.
Next expected catalyst
Interpretation of Phase 3 read-throughs and what they imply for metabolic approaches to AD.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and shared biology: alzheimer's with Semaglutide.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and shared biology: alzheimer's with Semaglutide.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Late-stage active active, not recruiting

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Shown because it shares same disease bench and shared biology: alzheimer's with Semaglutide.
Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Next catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and shared biology: alzheimer's with Semaglutide.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT04777396 ClinicalTrials.gov search Novo Nordisk pipeline
Scroll to Top